Public Release: 

Case report of a brain and spinal tumor following human fetal stem cell therapy

PLOS

A case report published in this week's issue of the open-access general medical journal, PLoS Medicine, describes a rare side effect of human fetal stem cell therapy. Ninette Amariglio and Gideon Rechavi from the Sheba Medical Center, Tel Aviv, Israel, and colleagues report the case of a boy with a rare genetic disease, Ataxia Telangiectasia, who underwent human fetal stem cell therapy at an unrelated clinic in Moscow and who, four years after the therapy began, was shown to have abnormal growths in his brain and spinal cord.

There have been reports in rodents of the development of tumors following the injection of pluripotential embryonic stem cells into recipient animals, although the risk of such tumors can be reduced if the cells are differentiated before being injected. However, this report is the first documented example of such a complication in a human following neural fetal stem cell therapy.

The spinal cord growth was surgically removed and this was shown to resemble a glioneuronal tumor - a type of benign neural tumor. The authors describe the process by which they analyzed the tumor and documented that it could not have arisen from the patient's own tissues. For example, the tumor contained both XX (female) and XY (male) cells and had two normal copies of the ATM gene (the gene causing Ataxia Telangiectasia, which was mutated in the patient).

The authors discuss the extremely rare nature of this side effect and speculate that the patient's underlying condition may itself have allowed the tumor to become established, since individuals with Ataxia Telangiectasia often have an impaired immune system. Although this report indicates the need for caution in stem cell therapy, the authors conclude that their findings "do not imply that the research in stem cell therapeutics should be abandoned. They do, however, suggest that extensive research into the biology of stem cells and in-depth preclinical studies, especially of safety, should be pursued in order to maximize the potential benefits of regenerative medicine while minimizing the risks."

###

Citation: Amariglio N, Hirshberg A, Scheithauer BW, Cohen Y, Loewenthal R, et al. (2009) Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med 6(2): e1000029. doi:10.1371/journal.pmed.1000029

IN YOUR COVERAGE PLEASE USE THIS URL TO PROVIDE ACCESS TO THE FREELY AVAILABLE PAPER: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.1000029

PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-06-02-rechavi.pdf

READ THE EDITORS' SUMMARY OF THE PAPER: http://www.plos.org/press/plme-06-02-rechavi-summary.pdf

CONTACT:
Ninette Amariglio
Head, Hematology and Molecular Biology Lab
Institute of Hematology & Cancer Research Center
Sheba Medical Center
Tel Hashomer 52621
Tel: 972-3-5302128
Fax: 972-3-5302377

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.